Piper Sandler analyst Edward Tenthoff lowered the firm’s price target on Arrowhead to $55 from $64 and keeps an Overweight rating on the shares after the company reported Phase II SEQUOIA data showing a dose dependent reduction in serum Z-ATT of 74% at 25mg, 89% at 100mg and 94% at 200mg fazirsiran at 48 weeks. The analyst dropped the price target to reflect the pushing out of fazirsiran approval.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ARWR:
- Takeda Pharmaceutical, Arrowhead announce topline results from SEQUOIA study
- Arrowhead announces $25M milestone payment from Amgen
- Piper recommends ‘down market cap’ biotech exposure for 2023
- Piper Sandler names three top biotechnology picks for 2023
- Horizon Therapeutics announces first subject does in HZN-457 trial
